Renal biopsy plays a pivotal role in cancer research, especially in understanding renal cell carcinoma (RCC), the most common form of kidney cancer. By obtaining tissue samples through biopsy, researchers can analyze genetic mutations, biomarkers, and cellular characteristics unique to RCC subtypes. This aids in personalized treatment strategies and drug development. Additionally, renal biopsies contribute to prognostic assessments, helping clinicians predict disease progression and patient outcomes. Advanced techniques like molecular profiling and immunohistochemistry enhance the precision of these analyses, guiding researchers towards novel therapeutic targets and prognostic indicators. Consequently, renal biopsy remains indispensable in advancing our understanding of RCC biology and improving clinical management for patients battling kidney cancer.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China